Loading...

MacroGenics

DB:M55
Snowflake Description

Flawless balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
M55
DB
$796M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
  • MacroGenics has significant price volatility in the past 3 months.
M55 Share Price and Events
7 Day Returns
-6.6%
DB:M55
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-24.2%
DB:M55
-10.6%
DE Biotechs
-6.2%
DE Market
M55 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MacroGenics (M55) -6.6% -16.9% 39.8% -24.2% -26% -4.8%
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • M55 underperformed the Biotechs industry which returned -10.6% over the past year.
  • M55 underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
M55
Industry
5yr Volatility vs Market
Related Companies

M55 Value

 Is MacroGenics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of MacroGenics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for MacroGenics.

DB:M55 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 12 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:M55
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.449 (1 + (1- 21%) (0%))
1.301
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.301 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:M55 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for MacroGenics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:M55 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -126.11 Analyst x4 -116.79
2020 -222.80 Analyst x3 -191.09
2021 0.11 Analyst x1 0.08
2022 65.68 Analyst x2 48.31
2023 91.58 Analyst x2 62.39
2024 112.78 Est @ 23.14% 71.14
2025 131.12 Est @ 16.27% 76.60
2026 146.14 Est @ 11.45% 79.07
2027 157.96 Est @ 8.09% 79.14
2028 167.01 Est @ 5.73% 77.49
Present value of next 10 years cash flows $186.36
DB:M55 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $167.01 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$2,159.03
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,159.03 ÷ (1 + 7.98%)10
$1,001.81
DB:M55 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $186.36 + $1,001.81
$1,188.17
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,188.17 / 48.80
$24.35
DB:M55 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:M55 represents 0.84807x of NasdaqGS:MGNX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.84807x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 24.35 x 0.84807
€20.65
Value per share (EUR) From above. €20.65
Current discount Discount to share price of €14.26
= -1 x (€14.26 - €20.65) / €20.65
31%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price MacroGenics is available for.
Intrinsic value
31%
Share price is €14.26 vs Future cash flow value of €20.65
Current Discount Checks
For MacroGenics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • MacroGenics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • MacroGenics's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MacroGenics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MacroGenics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:M55 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-4.19
NasdaqGS:MGNX Share Price ** NasdaqGS (2019-04-23) in USD $16.81
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MacroGenics.

DB:M55 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:MGNX Share Price ÷ EPS (both in USD)

= 16.81 ÷ -4.19

-4.01x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MacroGenics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • MacroGenics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does MacroGenics's expected growth come at a high price?
Raw Data
DB:M55 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.01x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts
27.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MacroGenics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MacroGenics's assets?
Raw Data
DB:M55 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $5.73
NasdaqGS:MGNX Share Price * NasdaqGS (2019-04-23) in USD $16.81
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:M55 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:MGNX Share Price ÷ Book Value per Share (both in USD)

= 16.81 ÷ 5.73

2.93x

* Primary Listing of MacroGenics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MacroGenics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess MacroGenics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. MacroGenics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

M55 Future Performance

 How is MacroGenics expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
27.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MacroGenics expected to grow at an attractive rate?
  • Unable to compare MacroGenics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare MacroGenics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • MacroGenics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:M55 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:M55 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 27.3%
DB:M55 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 12 Analysts 41.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:M55 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:M55 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 422 98 -17 8
2022-12-31 296 74 -55 9
2021-12-31 159 -20 -143 10
2020-12-31 72 -188 -203 12
2019-12-31 50 -118 -192 9
DB:M55 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 60 -153 -171
2018-09-30 197 -14 -21
2018-06-30 178 -9 -34
2018-03-31 160 18 -32
2017-12-31 158 14 -20
2017-09-30 10 -126 -160
2017-06-30 12 -45 -147
2017-03-31 91 -47 -66
2016-12-31 92 -44 -59
2016-09-30 95 -40 -52
2016-06-30 106 -97 -34
2016-03-31 32 -89 -96

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • MacroGenics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • MacroGenics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:M55 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from MacroGenics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:M55 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.21 2.17 -3.53 8.00
2022-12-31 -0.70 1.70 -1.77 8.00
2021-12-31 -2.28 -0.24 -3.50 8.00
2020-12-31 -3.75 -1.89 -5.49 10.00
2019-12-31 -3.93 -2.81 -4.61 9.00
DB:M55 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -4.19
2018-09-30 -0.53
2018-06-30 -0.89
2018-03-31 -0.86
2017-12-31 -0.54
2017-09-30 -4.50
2017-06-30 -4.19
2017-03-31 -1.89
2016-12-31 -1.69
2016-09-30 -1.51
2016-06-30 -0.99
2016-03-31 -2.89

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MacroGenics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess MacroGenics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MacroGenics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

M55 Past Performance

  How has MacroGenics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MacroGenics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MacroGenics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare MacroGenics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MacroGenics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
MacroGenics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MacroGenics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:M55 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 60.12 -171.45 40.50
2018-09-30 196.69 -21.08 38.36
2018-06-30 177.55 -34.10 37.18
2018-03-31 160.38 -31.51 34.43
2017-12-31 157.74 -19.63 32.65
2017-09-30 10.49 -160.14 33.48
2017-06-30 12.08 -146.94 32.31
2017-03-31 91.09 -65.82 31.16
2016-12-31 91.88 -58.53 29.83
2016-09-30 94.95 -52.20 27.31
2016-06-30 106.38 -33.79 26.11
2016-03-31 32.42 -95.63 24.22
2015-12-31 100.85 -20.14 22.77
2015-09-30 98.15 -10.71 20.90
2015-06-30 101.85 0.81 18.55
2015-03-31 104.36 9.92 17.35
2014-12-31 47.80 -38.31 15.93
2014-09-30 57.23 -19.56 14.85
2014-06-30 59.08 -15.46 13.15
2014-03-31 62.16 0.00 10.51
2013-12-31 58.04 -0.26 11.09
2013-09-30 52.93 0.00 10.87
2013-06-30 48.78 -0.21 10.40
2013-03-31 53.91 -3.40 10.55
2012-12-31 63.83 0.00 10.19

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MacroGenics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if MacroGenics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MacroGenics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess MacroGenics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MacroGenics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

M55 Health

 How is MacroGenics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MacroGenics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MacroGenics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MacroGenics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of MacroGenics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • MacroGenics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MacroGenics Company Filings, last reported 3 months ago.

DB:M55 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 242.88 0.00 232.86
2018-09-30 282.64 0.00 260.14
2018-06-30 312.04 0.00 300.89
2018-03-31 247.28 0.00 260.08
2017-12-31 299.24 0.00 305.12
2017-09-30 189.47 0.00 203.65
2017-06-30 231.35 0.00 243.66
2017-03-31 234.64 0.00 243.10
2016-12-31 268.75 0.00 277.00
2016-09-30 300.10 0.00 311.12
2016-06-30 329.98 0.00 265.62
2016-03-31 286.26 0.00 304.45
2015-12-31 313.34 0.00 339.05
2015-09-30 339.33 0.00 365.77
2015-06-30 211.69 0.00 235.03
2015-03-31 230.99 0.00 263.13
2014-12-31 121.29 0.00 157.59
2014-09-30 139.09 0.00 179.19
2014-06-30 141.98 0.00 194.01
2014-03-31 153.22 0.00 198.72
2013-12-31 78.91 0.00 116.48
2013-09-30 -3.37 0.00 33.57
2013-06-30 -10.81 0.00 33.78
2013-03-31 -11.27 0.00 43.53
2012-12-31 -8.18 0.00 47.74
  • MacroGenics has no debt.
  • MacroGenics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • MacroGenics has sufficient cash runway for 1.3 years based on current free cash flow.
  • MacroGenics has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 11% each year.
X
Financial health checks
We assess MacroGenics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MacroGenics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

M55 Dividends

 What is MacroGenics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MacroGenics dividends. Estimated to be 0% next year.
If you bought €2,000 of MacroGenics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MacroGenics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MacroGenics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:M55 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:M55 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MacroGenics has not reported any payouts.
  • Unable to verify if MacroGenics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MacroGenics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MacroGenics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of MacroGenics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess MacroGenics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MacroGenics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MacroGenics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

M55 Management

 What is the CEO of MacroGenics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Scott Koenig
COMPENSATION $3,478,130
AGE 66
TENURE AS CEO 17.6 years
CEO Bio

Dr. Scott Koenig, M.D., Ph.D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig served as Senior Vice President of Research at MedImmune Inc., where he participated in the selection and maturation of its product pipeline for 11 years. He has been the Chairman of Applied Genetic Technologies Corporation since April 2004. He serves as the Chairman of Applied Genetic Therapy Corporation. He is the co-chair of the Scientific Advisory Board of the Institute for Bioscience and Biotechnology Research (IBBR) at the University of Maryland. Dr. Koenig has been a Director of MacroGenics, Inc. since September 2001. From 1984 to 1990, he worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. He has been a Director of GlycoMimetics, Inc. since March 13, 2017. He is employee at MedImmune, LLC. He has been a Director of Applied Genetic Technologies Corporation since April 2002. He also serves as a Member of the Board of Directors of the Biotechnology Innovation Organization (BIO) and the International Biomedical Research Alliance. Dr. Koenig served as a Director of Children's National Health System until February 6, 2017. He is a member of the Board of Scientific Counselors at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health and was elected as a member of the Cornell University Council. He completed his residency in Internal Medicine at the Hospital of the University of Pennsylvania and is Board certified in Internal Medicine and Allergy and Immunology. Dr. Koenig received his A.B. and Ph.D. from Cornell University and his M.D. from the University of Texas Health Science Center in Houston, where he was elected to Alpha Omega Alpha.

CEO Compensation
  • Scott's compensation has increased whilst company is loss making.
  • Scott's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the MacroGenics management team in years:

5.7
Average Tenure
53.5
Average Age
  • The average tenure for the MacroGenics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Scott Koenig

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
66
TENURE
17.6 yrs

Jim Karrels

TITLE
Senior VP
COMPENSATION
$1M
AGE
51
TENURE
10.9 yrs

Ezio Bonvini

TITLE
Senior VP of Research & Chief Scientific Officer
COMPENSATION
$1M
AGE
64
TENURE
2.6 yrs

Eric Risser

TITLE
Senior VP of Business Development & Portfolio Management and Chief Business Officer
COMPENSATION
$1M
AGE
45
TENURE
2.6 yrs

Jon Wigginton

TITLE
Senior VP of Clinical Development & Chief Medical Officer
COMPENSATION
$2M
AGE
56
TENURE
5.7 yrs

Jeffrey Peters

TITLE
VP & General Counsel
AGE
47
TENURE
1.8 yrs

Tom Spitznagel

TITLE
Senior Vice President of BioPharmaceutical Development & Manufacturing
AGE
51

Lynn Cilinski

TITLE
VP, Controller & Treasurer
AGE
60
TENURE
15.5 yrs
Board of Directors Tenure

Average tenure and age of the MacroGenics board of directors in years:

5.6
Average Tenure
60
Average Age
  • The tenure for the MacroGenics board of directors is about average.
Board of Directors

Paulo Costa

TITLE
Chairman
COMPENSATION
$196K
AGE
67
TENURE
5.6 yrs

Scott Koenig

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
66
TENURE
17.6 yrs

Ken Galbraith

TITLE
Director
COMPENSATION
$179K
AGE
55
TENURE
10.8 yrs

Matt Fust

TITLE
Director
COMPENSATION
$182K
AGE
53
TENURE
5.1 yrs

Ed Hurwitz

TITLE
Director
COMPENSATION
$174K
AGE
55
TENURE
14.5 yrs

Dave Stump

TITLE
Director
COMPENSATION
$164K
AGE
68
TENURE
5.6 yrs

Karen Jean Ferrante

TITLE
Director
COMPENSATION
$382K
AGE
60
TENURE
2.3 yrs

Scott Jackson

TITLE
Director
COMPENSATION
$384K
AGE
53
TENURE
2.3 yrs

Jay Siegel

TITLE
Director
COMPENSATION
$230K
AGE
65
TENURE
1.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess MacroGenics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MacroGenics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

M55 News

Simply Wall St News

M55 Company Info

Description

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3; MGA012, an anti-PD-1 monoclonal antibody, which inhibits programmed cell death protein 1 (PD-1); MGD013, a monoclonal antibody that targets the immune checkpoints PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing MGD009, a DART molecule that targets B7-H3 expressed on tumor cells and CD3; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD007, a DART molecule, which targets glycoprotein A33 and CD3; and MGD014, a DART molecule that targets virus-infected cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and Zai Lab Limited. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.

Details
Name: MacroGenics, Inc.
M55
Exchange: DB
Founded: 2000
$710,351,295
48,804,476
Website: http://www.macrogenics.com
Address: MacroGenics, Inc.
9704 Medical Center Drive,
Rockville,
Maryland, 20850,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS MGNX Common Stock Nasdaq Global Select US USD 10. Oct 2013
DB M55 Common Stock Deutsche Boerse AG DE EUR 10. Oct 2013
Number of employees
Current staff
Staff numbers
364
MacroGenics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 21:51
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.